DeLLphi-306 is a Phase 3 clinical trial that is testing an investigational drug called tarlatamab. This clinical trial aims to see how safe and effective tarlatamab is at treating patients with small-cell lung cancer (SCLC) that has not progressed after they have completed chemoradiation. Participants will receive either tarlatamab or a placebo.
Talk to an Amgen Medical Information Healthcare Professional to see if you qualify.
Patients who are 18 years or older
Small-cell lung cancer (SCLC) diagnosis was confirmed by tumor sample under a microscope
Small-cell lung cancer (SCLC) is only in one lung, or one lung and nearby lymph nodes
Ongoing response or no progression after chemoradiation
Where can I get more information?
To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.
Step 1: Screening
At your first visit(s), you will:
*This may not be needed in all cases. Your doctor will let you know if this is not needed.
If you meet the requirements and decide to join this clinical trial, you will move on to Step 2.
Step 2: Treatment
Approximately 400 participants will be randomly assigned to receive either tarlatamab (investigational drug) or placebo.
The tarlatamab group will:
The placebo group will:
Step 3: End of treatment
You will continue to receive treatment in this clinical trial based on the results of your bloodwork and imaging. The treatment you receive in this trial or your participation in this clinical trial may end if:
The clinical trial team will schedule a follow-up visit with you approximately 9 weeks after your last trial treatment.
Step 4: Long term follow-up (up to 4 years)
The clinical trial team may follow-up with you by phone or ask you to visit the clinic approximately once every 6 months.
If you are a physician or another healthcare professional interested in learning more about a tarlatamab clinical trial or referring a patient, please contact an Amgen Medical Information Healthcare Professional.
Where can I get more information?
To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.